Heet Healthcare Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Heet Healthcare Private Limited Pharmaceutical Export Portfolio Dataset — 11 Products, $867.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Heet Healthcare Private Limited — Pharmaceutical Exporter Profile (2026) | 11 Products, $867.1K Trade | TransData Nexus

Heet Healthcare Private Limited

Indian Pharmaceutical Exporter · Antiviral & HIV Medications Specialist · $867.1K Total Trade · DGFT Verified

Heet Healthcare Private Limited is an Indian pharmaceutical exporter with a total trade value of $867.1K across 11 products in 2 therapeutic categories. Based on 297 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Sofosbuvir ($370.8K), Velpatasvir ($262.0K), Sorafenib ($76.4K).

Heet Healthcare Private Limited — Export Portfolio & Destination Treemap

Heet Healthcare Private Limited pharmaceutical export portfolio — 11 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Heet Healthcare Private Limited? — Company Overview & Market Position

Heet Healthcare Private Limited, incorporated on August 14, 2013, is a privately held pharmaceutical company based in Ahmedabad, Gujarat, India. The company's Corporate Identification Number (CIN) is U24230GJ2013PTC076430. Heet Healthcare specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has established a significant presence in the global pharmaceutical market, exporting products to over 15 countries.

The registered office is located at 507, 508, 5th Floor, The Emporio By Kunj, Opp. 4D Square Mall, Visat-Gandhinagar Highway, Ahmedabad, Gujarat, 382424, India. As of the latest available data, Heet Healthcare has an authorized and paid-up capital of ₹1 crore (approximately $130,000 USD). The company is led by Managing Director Devendra Mathuria, who has been associated with Heet Healthcare since its inception.

What Does Heet Healthcare Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Sofosbuvir$370.8K 2

Product Portfolio — Top 11 by Export Value

Heet Healthcare Private Limited exports 11 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Sofosbuvir	Antiviral & HIV Medications	$370.8K	116	0.9%	5
2	Velpatasvir	Antiviral & HIV Medications	$262.0K	63	1.1%	6
3	Sorafenib	Advanced Oncology	$76.4K	34	0.5%	4
4	Rituximab	Advanced Oncology	$58.3K	10	0.3%	13
5	Lenvatinib	Advanced Oncology	$27.4K	16	1.3%	10
6	Pazopanib	Advanced Oncology	$22.1K	8	0.3%	10
7	Gefitinib	Advanced Oncology	$16.3K	10	0.2%	10
8	Lapatinib	Advanced Oncology	$11.8K	4	0.2%	9
9	Ledipasvir	Antiviral & HIV Medications	$11.1K	19	1.0%	10
10	Olaparib	Advanced Oncology	$8.3K	10	0.9%	12
11	Cabozantinib	Advanced Oncology	$2.4K	7	1.9%	11

Heet Healthcare Private Limited exports 11 pharmaceutical products across 2 therapeutic categories with a total export value of $867.1K. The top category is Antiviral & HIV Medications (74.3% of portfolio), followed by Advanced Oncology (25.7%), indicating a concentrated portfolio with the top 5 products accounting for 91.7% of total export value.

Heet Healthcare Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Heet Healthcare operates manufacturing facilities in Ahmedabad, Gujarat, India. The company emphasizes adherence to Good Manufacturing Practices (GMP) and has achieved WHO-GMP certification, reflecting its commitment to maintaining high-quality standards in pharmaceutical production. The facilities are equipped with advanced technological equipment and high-quality raw materials, ensuring the production of safe, reliable, and effective pharmaceutical products.

3Key Leadership

The leadership team at Heet Healthcare Private Limited is headed by Managing Director Devendra Mathuria, who has been with the company since its incorporation in 2013. Another key executive is Snehal Devendrasingh Mathuria, who serves as a director and has been associated with the company since May 26, 2022. The leadership team is committed to upholding the company's mission of providing excellent quality products and maintaining the highest ethical standards in business practices.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Heet Healthcare Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Heet Healthcare Private Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company exports a diverse range of pharmaceutical products, with a significant focus on antiviral and oncology medications. While specific regulatory approvals in these markets are not detailed in the available sources, Heet Healthcare's adherence to WHO-GMP standards suggests compliance with international regulatory requirements.

2Emerging Markets

Heet Healthcare has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's commitment to quality and compliance with international standards, as evidenced by its WHO-GMP certification, facilitates access to these markets. By offering a range of pharmaceutical products, including antiviral and oncology medications, Heet Healthcare addresses the healthcare needs of these regions, contributing to improved patient outcomes.

3Geographic Strategy

Heet Healthcare's geographic strategy involves a balanced approach to market diversification and concentration. The company's export data indicates a strong presence in antiviral and oncology medication markets, with top products like Sofosbuvir, Velpatasvir, and Sorafenib. This focus suggests a strategic emphasis on high-demand therapeutic areas. While the company has expanded into emerging markets, the concentration in specific product categories may expose it to market fluctuations. To mitigate this risk, Heet Healthcare could consider diversifying its product portfolio and exploring additional therapeutic areas.

Heet Healthcare Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Heet Healthcare's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided sources. However, the company's adherence to WHO-GMP standards indicates a commitment to maintaining quality manufacturing practices, which is essential for obtaining approvals in regulated markets like the United States.

2WHO & EU GMP

Heet Healthcare Private Limited holds WHO-GMP certification, reflecting its compliance with international manufacturing standards. This certification underscores the company's commitment to producing pharmaceutical products that meet global quality benchmarks. While specific details regarding EU GMP certificates and EDQM status are not available in the provided sources, the WHO-GMP certification suggests that Heet Healthcare's manufacturing practices align with European Union standards.

3CDSCO & Indian Regulatory

Heet Healthcare Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Heet Healthcare Private Limited operates in a competitive pharmaceutical market, particularly in the antiviral and oncology medication segments. While specific competitors are not identified in the available sources, the company's focus on high-demand therapeutic areas positions it favorably. To enhance its competitive edge, Heet Healthcare could consider expanding its product portfolio, investing in research and development, and strengthening its presence in emerging markets.

2Key Differentiators

Heet Healthcare's key differentiators include its adherence to WHO-GMP standards, ensuring high-quality manufacturing processes, and its focus on high-demand therapeutic areas such as antiviral and oncology medications. The company's commitment to ethical business practices and customer satisfaction further distinguishes it in the pharmaceutical industry.

3Strategic Position

Heet Healthcare Private Limited's current strategic direction emphasizes the production and export of generic pharmaceutical formulations, particularly in the antiviral and oncology sectors. The company's WHO-GMP certification and focus on high-quality manufacturing practices support this strategy. Looking ahead, Heet Healthcare may consider expanding into specialty pharmaceuticals, biosimilars, or contract development and manufacturing (CDMO) services to diversify its offerings and enhance its market position.

Buyer Due Diligence Brief — Evaluating Heet Healthcare Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Heet Healthcare Private Limited has demonstrated a consistent track record in pharmaceutical manufacturing, with a total export value of $867,000 USD across 297 shipments from 2022 to 2026. The company's focus on high-quality manufacturing, as evidenced by its WHO-GMP certification, indicates reliability in product quality and supply consistency. However, specific reliability indicators are not detailed in the available sources.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration. Verification can be done through the FDA's official website or by contacting the FDA directly.

WHO-GMP Certification: Ensure that the manufacturing facilities are certified by the World Health Organization's Good Manufacturing Practices. This can be verified by reviewing the company's certification documents or contacting the WHO.

Frequently Asked Questions — Heet Healthcare Private Limited

How many pharmaceutical products does Heet Healthcare Private Limited export from India?

Heet Healthcare Private Limited exports 11 pharmaceutical products across 2 therapeutic categories. The top exports are Sofosbuvir ($370.8K), Velpatasvir ($262.0K), Sorafenib ($76.4K), Rituximab ($58.3K), Lenvatinib ($27.4K). Total export value is $867.1K.

What is Heet Healthcare Private Limited's total pharmaceutical export value?

Heet Healthcare Private Limited's total pharmaceutical export value is $867.1K, based on 297 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Heet Healthcare Private Limited cover?

Heet Healthcare Private Limited exports across 2 therapeutic categories. The largest are Antiviral & HIV Medications (74.3%, 3 products), Advanced Oncology (25.7%, 8 products).

Get Full Heet Healthcare Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.